ClinicalTrials.gg
Not yet recruitingNCT05973149Updated Aug 2, 2023

Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer

A Phase 1 interventional study of QLH12016 in Prostate Cancer, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 2 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-02.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 541 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 51 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
201st of 435
108 · median 100
Started
2023
with 58 others
Phase 1
97 of 541
54 open now
Primary completion
2025-08
later than 70 of 341 live
Registered
247th of 541
by date

Among the 541 studies in Prostatic Neoplasms with a site in China, this one is the 201st largest by planned enrollment of the 435 interventional ones that give a count, is one of 59 that started in 2023, is one of 97 in phase 1, reaches primary completion later than 70 of the 341 other live ones, and was the 247th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 541 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 541 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer

Read the detailed description

Subjects will use QLH12016 for the treatment of mCRPC.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign a written form
  2. Male, aged ≥ 18 years
  3. :0-1
  4. Expected survival time of at least 3 months
  5. Prostate adenocarcinoma confirmed by histological or cytological without neuroendocrine or small cell characters
  6. Continuous treatment with luteinizing hormone releasing hormone analogue or luteinizing hormone releasing hormone antagonist (drug castration), or previous bilateral orchiectomy (surgical castration); Subjects who did not receive bilateral orchiectomy must plan to maintain effective luteinizing hormone releasing hormone analog or luteinizing hormone releasing hormone antagonist treatment throughout the study period
  7. testosterone≤50 ng/dL or 1.7 nmol/L
  8. CRPC is defined as the occurrence of one or more of the following three events in a subject while undergoing castration treatment: ① PSA progression, defined as at least two increases in PSA levels (PSA value>1 ng/mL, interval of at least 1 week, consecutive 2 times, increase>50% from baseline); ② Disease progression as defined in v1.1; ③ The progression of skeletal diseases as defined by the PCWG3 standard, where bone scans reveal ≥ 2 or more new lesions
  9. lesion with imaging evidence. At least one target lesion exists
  10. Received 1-2 lines of new endocrine therapy (such as enzalutamide, abiolone, etc.) after developing castration resistance(ArmA-C)
  11. Received 0-1 line chemotherapy treatment (such as docetaxel) during the hormone sensitive period and the castration resistance period(ArmA-C)
  12. Arm B: with specific biomarkers; Arm C: without specific biomarkers; Arm D: received 0 or 1 line of new endocrine therapy, and no chemotherapy during hormone sensitive and castration resistant stages
  13. The functional level of important organs must meet the following requirements (no blood components, hematopoietic stimulating factors, cell growth factors, leukemic drugs, enhancing drugs, etc. are allowed to be used within 7 days before obtaining laboratory examination): ≥ 1.5 × 10\^9/L; Platelets ≥ 100 × 10\^9/L; ≥ 100 g/L; Serum albumin ≥ 30 g/L; and ALT ≤ 2.5 × reference value (ULN), if accompanied by liver metastasis, ALT and AST ≤ 5 × ULN; Total ≤ 1.5 × ULN (Gilbert syndrome≤ 3 × ULN); Serum creatinine ≤ 1.5 × ULN, if >1.5 × ULN, then the rate (CLcr) ≥ 50 mL/min; >50%
  14. Effective measures from signing the informed consent to 90 days after the last use of the study drug
  15. Recover from all AEs of previous anti-cancer treatment (i.e. ≤ grade 1, according to v5.0), excluding alopecia (any grade) and peripheral sensory nerve ≤ grade 2, hypomagnesemia or lymphocytopenia, as well as other abnormalities that the benefit of receiving treatment is greater than the risk

Exclusion criteria

Exclusion Criteria:

  1. of the central nervous system (CNS), or spinal cord compression caused by metastasis (exceeding the physiological alternative dose) requiring hormone treatment
  2. Radiation therapy that has irradiated more than 25% of the bone marrow was performed within 4 weeks. Palliative radiation therapy is allowed to alleviate pain caused by bone metastasis during the study period
  3. Treatment with similar drugs
  4. Received other clinical trial drugs or major surgeries within 4 weeks (sufficient wound healing after major surgeries must undergo clinical evaluation)
  5. Systemic anti-cancer treatment within the first 2 weeks (bicalutamide, Mitomycin C or Nitroso urea 6 weeks, enzalutamide 5 weeks, and abiolone 4 weeks). Medications that maintain castration are allowed.
  6. Planned bilateral orchiectomy during the study treatment
  7. Inability to swallow, chronic diarrhea and bowel obstruction, or other factors affecting drug administration and absorption
  8. Epilepsy or disease that can induce seizure within 12 months (including a history of , stroke, brain trauma with disorders of consciousness, etc.)
  9. History of psychotropic substance abuse, alcoholism, or drug use, neurological or mental disorders, including dementia or hepatic encephalopathy
  10. Any of the following conditions occurs within 12 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass grafting, symptomatic congestive heart failure ( III or IV), cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism or other thromboembolic diseases with clinical significance
  11. Any of the following conditions within 6 months: congenital long syndrome, torsade de pointes ventricular tachycardia, arrhythmia (including persistent ventricular tachyarrhythmia and Ventricular fibrillation), left anterior half block (double vessel block) or persistent arrhythmia above grade 2, Atrial fibrillation of any level (in the case of Asymptomatic isolated Atrial fibrillation, grade ≥ 2)
  12. Cardiovascular diseases under poor control, including angina pectoris, pulmonary hypertension or serious cardiac rhythm or conduction abnormalities
  13. QTcF>450 ms
  14. Active, uncontrolled bacterial, fungal, or viral infections, including but not limited to: 1) Active virus (HBV), virus (HCV) infected persons (hepatitis B surface antigen [HBsAg] positive or hepatitis B core antibody [HBcAb] positive, HBV DNA virus copy number ≥ 500 IU/mL, HCV antibody positive and HCV RNA higher than the detection limit of the analysis method); 2) Syphilis required treatment; 3) History of congenital immunodeficiency or organ transplantation, or (HIV) positive
  15. Clinically uncontrollable third space effusion, such as pleural effusion, peritoneal effusion, pericardial effusion, etc. that cannot be controlled by drainage or other measures and cannot be included in the group according to the judgment of the investigator
  16. Other malignant tumors within 5 years (excluding cured basal cell skin cancer, papillary thyroid cancer, etc.)
  17. Concomitant diseases seriously endangering the safety of the subject or affect the completion of the study, such as hypertension (systolic pressure ≥ 160 mmHg and/or diastolic pressure ≥ 100 mmHg) that cannot be controlled by two or more antihypertensive drugs, diabetes not well controlled, etc
  18. History of hypertensive crisis or hypertensive encephalopathy
  19. Allergy to any study drug component
  20. Gastrointestinal perforation, gastrointestinal or non gastrointestinal fistula, or abdominal abscess within 6 months
  21. Any life-threatening bleeding event within 3 months, including the need for blood transfusion treatment, surgery or local treatment, and continuous medication treatment
  22. Subjects who may increase research related risks, interfere with the interpretation of research results, or are deemed unsuitable for inclusion by the researcher
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    QLH12016 dose escalation

    Daily dosages are predetermined by Safety Monitoring Committee after the initial starting dose cohort at the end of Cycle 1 (each cycle is 28 days)

    Drug: QLH12016

  • Experimental
    QLH12016 in mCRPC with specific biomarkers

    Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A

    Drug: QLH12016

  • Experimental
    QLH12016 in mCRPC without specific biomarkers

    Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A

    Drug: QLH12016

  • Experimental
    QLH12016 in less pretreated mCRPC

    Daily dosage and schedule at a recommended Phase 2 dose based on data from Arm A

    Drug: QLH12016

Interventions

  • according to the scheme description

06

What researchers measure

Primary outcomes

  1. Arm A: Incidence of Dose Limiting Toxicities

    First Cycle Dose limiting toxicities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug

    Time frame: 28 Days

  2. Arm A:Maximum Tolerated Dose

    The Maximum Tolerated Dose determined by the Incidence of Dose Limiting Toxicities

    Time frame: 28 Days

  3. Arm A:Recommended Phase 2 Dose

    Recommended Phase 2 Dose determined by the frequency of Incidence of Dose Limiting Toxicities

    Time frame: 28 Days

  4. Arm A:AE

    The incidence, severity and correlation with the study drug of adverse events (AEs) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0

    Time frame: 20 weeks

  5. Arm A:SAE

    The incidence, severity and correlation with the study drug of Serious adverse event (SAE) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0

    Time frame: 20 weeks

  6. Arm B-D:PSA Response Rate

    a decrease of ≥ 50% in PSA levels from baseline to baseline, and reassessed PSA relief after ≥ 3 weeks in each arm

    Time frame: 20 weeks

  7. Arm B-D:Objective Response Rate

    the percentage of "CR/PR" subjects in each arm

    Time frame: 20 weeks

Secondary outcomes

  1. Cmax

    The highest plasma drug concentration

    Time frame: 20 weeks

  2. Tmax

    The time blood drug concentration reaching Cmax

    Time frame: 20 weeks

  3. AUC

    The area enclosed by the drug time curve and the time axis

    Time frame: 20 weeks

  4. Arm A:ORR

    the percentage of "CR/PR" subjects

    Time frame: 20 weeks

  5. Arm A:PSA Response Rate

    a decrease of ≥ 50% in PSA levels from baseline to baseline, and reassessed PSA relief after ≥ 3 weeks

    Time frame: 20 weeks

  6. Arm B-D:AE

    The incidence, severity and correlation with the study drug of adverse events (AEs) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0

    Time frame: 20 weeks

  7. Arm B-D:SAE

    The incidence, severity and correlation with the study drug of Serious adverse event (SAE) evaluated according to the National Cancer Institute (NCI) - General Terminology of Adverse Events (CTCAE) Version 5.0

    Time frame: 20 weeks

  8. DOR

    The time between the initial evaluation of CR or PR and disease progression

    Time frame: 20 weeks

  9. DCR

    the percentage of "CR/PR/SD" subjects

    Time frame: 20 weeks

  10. rPFS

    The time between the first administration of the investigational drug and the first recording of disease progression (determined according to RECIST v1.1 and PCWG3) or the date of all-cause death (whichever occurs first)

    Time frame: 20 weeks

  11. OS

    The time between the first trial drug administration and patient death due to various reasons

    Time frame: 20 weeks

Other outcomes

  1. Biomarkers

    Using next-generation sequencing,reverse transcription DNA and quantitative polymerase chain reaction to evaluate tumor mutational burden and other signal pathway indicators

    Time frame: 20 weeks

07

Study locations

2 sites
  • Department of Urology, Peking University First Hospital
    Beijing, Beijign 100034, China
  • Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine
    Nanjing, Jiangsu 210008, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Aug 2025, 24 months later.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 24 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2023
First posted
Aug 2, 2023
StartEst.
Aug 31, 2023
Primary completionEst.
Aug 31, 2025
CompletionEst.
Jan 1, 2026
Last update
Aug 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05973149
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Aug 31, 2023 (estimated)
Primary completion
Aug 31, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Aug 2, 2023

Study contacts

Zhisong He, Phd
Contact
wyj7074@sohu.com
8613910688432
Zhisong He, Phd
principal investigator · Department of Urology, Peking University First Hospital
Hongqian Guo, Phd
principal investigator · Department of Urology, Drum Tower Hospital, Nanjing University School of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QLH12016

Start the discussion